Related Experiment Video

Updated: Aug 15, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Transforming growth factor beta and prostate cancer

Brian Zhu1, Natasha Kyprianou

  • 1Division of Urology, Department of Surgery, University of Kentucky, Lexington, KY, USA.

Cancer Treatment and Research
|October 8, 2005
PubMed

Insights

Transforming growth factor-beta (TGF-beta) regulates prostate cell functions and tumor suppression. Targeting TGF-beta signaling, particularly its receptor TbetaRII, shows promise for prostate cancer treatment and diagnosis.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Signaling

Background:

  • The TGF-beta superfamily regulates critical prostate cell processes including proliferation, apoptosis, and differentiation.
  • TGF-beta signaling is implicated in the development of osteoblastic metastases in prostate cancer.
  • The complex TGF-beta pathway involves receptor binding, kinase activation, Smad signaling, and gene transcription.

Purpose of the Study:

  • To explore the multifaceted role of TGF-beta in prostate cancer, including its tumor suppressor functions.
  • To investigate the therapeutic potential of targeting TGF-beta signaling pathways in prostate cancer.
  • To highlight the significance of TGF-beta receptor type II (TbetaRII) as a potential therapeutic target.

Main Methods:

  • Analysis of TGF-beta signaling pathways in prostate cells.
  • Investigation of Smad activation and its interplay with other signaling pathways like the androgen receptor.
  • Evaluation of TGF-beta's role in apoptosis and tumor suppression within the prostate microenvironment.

Main Results:

  • TGF-beta superfamily members exhibit versatile regulatory functions in prostate cancer.
  • The TGF-beta pathway's role in tumor suppression is context-dependent on the tissue microenvironment.
  • TbetaRII is identified as a key receptor with potential tumor suppressor activity.

Conclusions:

  • Targeting TGF-beta signaling, especially TbetaRII, is a promising therapeutic strategy for prostate cancer.
  • Understanding TGF-beta's complex role in prostate cancer progression and suppression is crucial for clinical applications.
  • Further research into TGF-beta's interaction with the tumor microenvironment can enhance treatment and diagnostic approaches for prostate cancer.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...